TY - JOUR
T1 - Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia
AU - Kudo, K.
AU - Muramatsu, H.
AU - Yoshida, N.
AU - Kobayashi, R.
AU - Yabe, H.
AU - Tabuchi, K.
AU - Kato, K.
AU - Koh, K.
AU - Takahashi, Y.
AU - Hashii, Y.
AU - Kawano, Y.
AU - Inoue, M.
AU - Cho, Y.
AU - Sakamaki, H.
AU - Kawa, K.
AU - Kato, K.
AU - Suzuki, R.
AU - Kojima, S.
N1 - Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - The outcome of 55 children with severe aplastic anemia (SAA) who received a second hematopoietic stem cell transplantation (HSCT) was retrospectively analyzed using the registration data of the Japanese Society for Hematopoietic Cell Transplantation. The 5-year overall survival (OS) and failure-free survival (FFS) after the second transplantation were 82.9% (95% confidence interval (CI), 69.7-90.8)) and 81.2% (95% CI, 67.8-89.4), respectively. FFS was significantly better when the interval between the first and second transplantation was >60 days (88.9%; 95% CI, 73.0-95.7) than when it was ≤60 days (61.4%; 95% CI, 33.3-80.5; P=0.026). All 12 patients who were conditioned with regimens containing fludarabine and melphalan were alive with hematopoietic recovery. These findings justify the recommendation of a second HSCT for children with SAA who have experienced graft failure after first HSCT.
AB - The outcome of 55 children with severe aplastic anemia (SAA) who received a second hematopoietic stem cell transplantation (HSCT) was retrospectively analyzed using the registration data of the Japanese Society for Hematopoietic Cell Transplantation. The 5-year overall survival (OS) and failure-free survival (FFS) after the second transplantation were 82.9% (95% confidence interval (CI), 69.7-90.8)) and 81.2% (95% CI, 67.8-89.4), respectively. FFS was significantly better when the interval between the first and second transplantation was >60 days (88.9%; 95% CI, 73.0-95.7) than when it was ≤60 days (61.4%; 95% CI, 33.3-80.5; P=0.026). All 12 patients who were conditioned with regimens containing fludarabine and melphalan were alive with hematopoietic recovery. These findings justify the recommendation of a second HSCT for children with SAA who have experienced graft failure after first HSCT.
UR - https://www.scopus.com/pages/publications/84943455571
UR - https://www.scopus.com/pages/publications/84943455571#tab=citedBy
U2 - 10.1038/bmt.2015.153
DO - 10.1038/bmt.2015.153
M3 - Article
C2 - 26121106
AN - SCOPUS:84943455571
SN - 0268-3369
VL - 50
SP - 1312
EP - 1315
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 10
ER -